Focus Area Oncology

The Client

  • Midsize Pharmaceutical company with T-cell modulating technology platform developing therapies for autoimmune and allergic diseases and conditions
  • Pipeline consists of a single early clinical asset advancing for rheumatoid arthritis (with long runway to value inflection) and multiple preclinical assets


  • Select top AIID indications to validate platform, balance development and commercial risk, and enable optionality to go-to-market alone vs needing a partner
  • Prepare development strategy and roadmap, accounting for differential time, value, cost and risk, to strategically sequence asset advancement and build a robust pipeline


  • Secondary research and KOL workshops to inform assessment of technology platform and pipeline strategy
  • Identified and ranked and developed target product profiles (TPPs) for platform-leverageable AIID indications
  • Developed development roadmap for select AIID indications and Board deck supporting recommendations

Valued Outcome

  • Rationale and selection of top platform-leverageable AIID indications
  • TPPs of select AIID indications to inform development
  • Development strategy and roadmap balancing time, value, cost and risk to build robust AIID pipeline and generate significant near- and long-term value